Abstract
The rapid spread of SARS-CoV-2 has gravely impacted societies around the world. Outbreaks in different parts of the globe are shaped by repeated introductions of new lineages and subsequent local transmission of those lineages. Here, we sequenced 3940 SARS-CoV-2 viral genomes from Washington State to characterize how the spread of SARS-CoV-2 in Washington State (USA) was shaped by differences in timing of mitigation strategies across counties, as well as by repeated introductions of viral lineages into the state. Additionally, we show that the increase in frequency of a potentially more transmissible viral variant (614G) over time can potentially be explained by regional mobility differences and multiple introductions of 614G, but not the other variant (614D) into the state. At an individual level, we see evidence of higher viral loads in patients infected with the 614G variant. However, using clinical records data, we do not find any evidence that the 614G variant impacts clinical severity or patient outcomes. Overall, this suggests that at least to date, the behavior of individuals has been more important in shaping the course of the pandemic than changes in the virus.
One Sentence Summary Local outbreak dynamics of SARS-CoV-2 in Washington State (USA) were driven by regionally different mitigation measures and repeated introductions of unique viral variants with different viral loads.
Competing Interest Statement
Janet A. Englund is a consultant for Sanofi Pasteur and Meissa Vaccines, Inc., and receives research support from GlaxoSmithKline, AstraZeneca, and Novavax. Helen Chu is a consultant for Merck and GlaxoSmithKline. Jay Shendure is a consultant with Guardant Health, Maze Therapeutics, Camp4 Therapeutics, Nanostring, Phase Genomics, Adaptive Biotechnologies, and Stratos Genomics, and has a research collaboration with Illumina. Michael Boeckh is a consultant for Merck and VirBio. Nicola F. Mueller, Cassia Wagner, Chris D. Frazar, Pavitra Roychoudhury, Jover Lee, Louise H. Moncla, Benjamin Pelle, Matthew Richardson, Erica Ryke, Hong Xie, Lasata Shrestha, Amin Addetia, Victoria M. Rachleff, Nicole A. P. Lieberman, Meei-Li Huang, Romesh Gautom, Geoff Melly, Brian Hiatt, Philip Dykema, Amanda Adler, Elisabeth Brandstetter, Peter D. Han, Kairsten Fay, Misja Ilcisin, Kirsten Lacombe, Thomas R. Sibley, Melissa Truong, Caitlin R. Wolf, Michael Famulare, Barry R. Lutz, Mark J. Rieder, Matthew Thompson, Jeff S. Duchin, Lea M. Starita, Keith R. Jerome, Scott Lindquist, Alexander L. Greninger, Deborah A. Nickerson, and Trevor Bedford declare no competing interests.
Funding Statement
NFM is funded by the Swiss National Science Foundation (P2EZP3_191891). JS is an Investigator of the Howard Hughes Medical Institute. TB is a Pew Biomedical Scholar and is supported by NIH R35 GM119774-01. The Seattle Flu Study is run through the Brotman Baty Institute for Precision Medicine and funded by Gates Ventures, the private office of Bill Gates.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Sequencing and analysis of samples from the Seattle Flu Study was approved by the institutional review board at the University of Washington (protocol STUDY00006181). Informed consent was obtained for all community participant samples and survey data. Informed consent for residual sample and clinical data collection was waived. Sequencing and analysis of samples from SCAN was approved by the institutional review board at the University of Washington (protocol STUDY00010432). Informed consent was obtained for all community participant samples and survey data. For UW Virology Lab, use of residual clinical specimens was approved by the institutional review board at the University of Washington (protocol STUDY00000408) with a waiver of informed consent.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data and code associated with this work are available at https://github.com/blab/ncov-wa-phylodynamics and https://github.com/blab/ncov-wa-d614g. SARS-CoV-2 consensus genome sequences associated with this work have been uploaded to Genbank and the GISAID EpiFlu database and accession numbers are available in supplementary data.
https://github.com/blab/ncov-wa-phylodynamics
